Ewopharma is the successor company to M.R. Leclerc & Co., founded in 1959. From the start, our focus has been on building bridges to the pharmaceutical markets of Central Eastern Europe. Much has changed in the region since 1959 – both economically and politically – and over this period we have gained an in-depth understanding of the markets and an esteemed standing there.
While we started out purely as a marketing partner for pharmaceutical companies, we have since acquired and launched proprietary products. Our brand Revalid® – a product line for holistic hair care and hair loss treatment–was developed in 1992 in Switzerland. In 2011, we acquired Irish healthcare company Newport Pharmaceuticals Ltd. giving us full ownership of the antiviral drug Isoprinosine® in 2011.Overseen by our head office in Schaffhausen, Switzerland, we now channel our industry knowledge and experience into the successful placement of both Ewopharma and partner brands in our target markets. In 2004, we joined the RX-Alliance, a professional cooperation network of successful pharmaceutical companies active in selected European markets.

Pharmaceutical

Ewopharma

Alain Staub

Reto Schaberl

Antonio Mantarro

Andreas Kübler

The Medical and Regulatory Affairs team at Ewopharma is responsible for ensuring compliance with regulatory standards and managing the approval processes for pharmaceutical products in Central Eastern Europe. This team collaborates with medical representatives to provide scientific support and information, oversees pharmacovigilance to monitor drug safety, and develops strategies for successful market entry and product promotion in alignment with local regulations. Their role is crucial in bridging the gap between the company's pharmaceutical offerings and regulatory requirements, ensuring safe and effective products reach the market.

Medical and Regulatory Affairs

About

Team members

Other teams at Ewopharma

Marketing and Sales

Business Management